These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 29194575)

  • 1. Controversies associated with the identification of the true origins of human neutrophils.
    Silvestre-Roig C; Brandau S
    J Leukoc Biol; 2024 Apr; 115(5):797-800. PubMed ID: 38412285
    [No Abstract]   [Full Text] [Related]  

  • 2. Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.
    Del Giudice G; Rappuoli R; Didierlaurent AM
    Semin Immunol; 2018 Oct; 39():14-21. PubMed ID: 29801750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCR2- and Flt3-Dependent Inflammatory Conventional Type 2 Dendritic Cells Are Necessary for the Induction of Adaptive Immunity by the Human Vaccine Adjuvant System AS01.
    Bosteels C; Fierens K; De Prijck S; Van Moorleghem J; Vanheerswynghels M; De Wolf C; Chalon A; Collignon C; Hammad H; Didierlaurent AM; Lambrecht BN
    Front Immunol; 2020; 11():606805. PubMed ID: 33519816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toll-like receptor 4 signaling in hematopoietic-lineage cells contributes to the enhanced activity of the human vaccine adjuvant AS01.
    Van Maele L; Fougeron D; Cayet D; Chalon A; Piccioli D; Collignon C; Sirard JC; Didierlaurent AM
    Eur J Immunol; 2019 Dec; 49(12):2134-2145. PubMed ID: 31489613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant Systems for vaccines: 13 years of post-licensure experience in diverse populations have progressed the way adjuvanted vaccine safety is investigated and understood.
    Laupèze B; Hervé C; Di Pasquale A; Tavares Da Silva F
    Vaccine; 2019 Sep; 37(38):5670-5680. PubMed ID: 31420171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity.
    Shi S; Zhu H; Xia X; Liang Z; Ma X; Sun B
    Vaccine; 2019 May; 37(24):3167-3178. PubMed ID: 31047671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFNγ response promoting vaccine immunogenicity.
    Coccia M; Collignon C; Hervé C; Chalon A; Welsby I; Detienne S; van Helden MJ; Dutta S; Genito CJ; Waters NC; Deun KV; Smilde AK; Berg RAVD; Franco D; Bourguignon P; Morel S; Garçon N; Lambrecht BN; Goriely S; Most RV; Didierlaurent AM
    NPJ Vaccines; 2017; 2():25. PubMed ID: 29263880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
    Garçon N; Van Mechelen M
    Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adjuvant system AS01 up-regulates neutrophil CD14 expression and neutrophil-associated antigen transport in the local lymphatic network.
    Neeland MR; Shi W; Collignon C; Meeusen ENT; Didierlaurent AM; de Veer MJ
    Clin Exp Immunol; 2018 Apr; 192(1):46-53. PubMed ID: 29194575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Lymphatic Immune Response Induced by the Adjuvant AS01: A Comparison of Intramuscular and Subcutaneous Immunization Routes.
    Neeland MR; Shi W; Collignon C; Taubenheim N; Meeusen EN; Didierlaurent AM; de Veer MJ
    J Immunol; 2016 Oct; 197(7):2704-14. PubMed ID: 27549170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells.
    Didierlaurent AM; Collignon C; Bourguignon P; Wouters S; Fierens K; Fochesato M; Dendouga N; Langlet C; Malissen B; Lambrecht BN; Garçon N; Van Mechelen M; Morel S
    J Immunol; 2014 Aug; 193(4):1920-30. PubMed ID: 25024381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination.
    Leroux-Roels G; Van Belle P; Vandepapeliere P; Horsmans Y; Janssens M; Carletti I; Garçon N; Wettendorff M; Van Mechelen M
    Vaccine; 2015 Feb; 33(8):1084-91. PubMed ID: 25444781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant system AS01: helping to overcome the challenges of modern vaccines.
    Didierlaurent AM; Laupèze B; Di Pasquale A; Hergli N; Collignon C; Garçon N
    Expert Rev Vaccines; 2017 Jan; 16(1):55-63. PubMed ID: 27448771
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.